[{"address1": "500 Unicorn Park Drive", "address2": "Suite 303", "city": "Woburn", "state": "MA", "zip": "01801", "country": "United States", "phone": "781 222 9600", "website": "https://www.replimune.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.", "fullTimeEmployees": 331, "companyOfficers": [{"maxAge": 1, "name": "Mr. Philip  Astley-Sparke F.S.A.", "age": 53, "title": "Executive Chairman", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 960520, "exercisedValue": 0, "unexercisedValue": 435967}, {"maxAge": 1, "name": "Ms. Emily Luisa Hill", "age": 44, "title": "Chief Financial Officer", "yearBorn": 1980, "fiscalYear": 2024, "totalPay": 593047, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Konstantinos  Xynos M.B.A., M.D., Ph.D.", "age": 57, "title": "Chief Medical Officer", "yearBorn": 1967, "fiscalYear": 2024, "totalPay": 668686, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sushil  Patel Ph.D.", "age": 53, "title": "CEO & Director", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 665050, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Robert  Coffin Ph.D.", "age": 59, "title": "Founder, Chief Scientist & Director", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 785888, "exercisedValue": 0, "unexercisedValue": 5822722}, {"maxAge": 1, "name": "Mr. Andrew  Schwendenman", "age": 48, "title": "Chief Accounting Officer & Treasurer", "yearBorn": 1976, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher  Sarchi", "age": 55, "title": "Chief Commercial Officer", "yearBorn": 1969, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Paul  Bullock", "title": "Chief Manufacturing Officer & Framingham Site Head", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 8, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1735689600, "compensationAsOfEpochDate": 1735603200, "maxAge": 86400, "priceHint": 2, "previousClose": 13.75, "open": 13.68, "dayLow": 13.0, "dayHigh": 13.78, "regularMarketPreviousClose": 13.75, "regularMarketOpen": 13.68, "regularMarketDayLow": 13.0, "regularMarketDayHigh": 13.78, "beta": 1.193, "forwardPE": -6.0266075, "volume": 711220, "regularMarketVolume": 711220, "averageVolume": 877910, "averageVolume10days": 1005590, "averageDailyVolume10Day": 1005590, "bid": 9.85, "ask": 16.83, "bidSize": 200, "askSize": 200, "marketCap": 1045829312, "fiftyTwoWeekLow": 4.92, "fiftyTwoWeekHigh": 17.0, "fiftyDayAverage": 12.247, "twoHundredDayAverage": 9.993175, "currency": "USD", "enterpriseValue": 573858048, "floatShares": 43825478, "sharesOutstanding": 76955800, "sharesShort": 6606061, "sharesShortPriorMonth": 5582789, "sharesShortPreviousMonthDate": 1732838400, "dateShortInterest": 1735603200, "sharesPercentSharesOut": 0.0858, "heldPercentInsiders": 0.04183, "heldPercentInstitutions": 0.92487997, "shortRatio": 8.77, "shortPercentOfFloat": 0.1184, "impliedSharesOutstanding": 76955800, "bookValue": 5.577, "priceToBook": 2.436794, "lastFiscalYearEnd": 1711843200, "nextFiscalYearEnd": 1743379200, "mostRecentQuarter": 1727654400, "netIncomeToCommon": -213022000, "trailingEps": -3.04, "forwardEps": -2.69, "enterpriseToEbitda": -2.531, "52WeekChange": 0.675709, "SandP52WeekChange": 0.23809385, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "REPL", "underlyingSymbol": "REPL", "shortName": "Replimune Group, Inc.", "longName": "Replimune Group, Inc.", "firstTradeDateEpochUtc": 1532093400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EST", "uuid": "ea19e92f-8d00-3fa8-9834-419bd79af5bf", "messageBoardId": "finmb_571664452", "gmtOffSetMilliseconds": -18000000, "currentPrice": 13.59, "targetHighPrice": 31.0, "targetLowPrice": 14.0, "targetMeanPrice": 20.0, "targetMedianPrice": 17.5, "recommendationMean": 1.625, "recommendationKey": "buy", "numberOfAnalystOpinions": 8, "totalCash": 432059008, "totalCashPerShare": 6.315, "ebitda": -226706000, "totalDebt": 76124000, "quickRatio": 9.913, "currentRatio": 10.108, "debtToEquity": 19.956, "returnOnAssets": -0.27066, "returnOnEquity": -0.50321996, "freeCashflow": -113402000, "operatingCashflow": -181095008, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2025-01-25"}]